Breast Cancer Therapeutics in Asia-Pacific Markets to 2024

by Sameer Joshi or 01-May-2018

Asia-Pacific (APAC) breast cancer market was valued at $2.16 billion in 2017, and is expected to grow at a compound annual growth rate (CAGR) of 11.9% to reach $4.75 billion in 2024.

The major factors that are expected to drive the market include increases in diagnosed prevalence and the annual cost of therapy (ACoT) due to higher uptake of costlier therapies. Older women are at a higher risk of developing breast cancer. The aging population, changing lifestyle habits and improved survival rates will increase the prevalence of breast cancer and be the driving factors underlying the forecast market growth. Additionally, the implementation of nationwide breast cancer screening programs in Asia-Pacific will contribute to an increase in the diagnosis of early-stage disease.

Breast cancer is not a single disease, but rather a group of several different tumor subtypes. Although many subtypes exist, they are generally categorized by the presence or absence of the ER, PR, and HER2. Broadly, patients can be segmented into two types: the human epidermal growth factor receptor (HER)2-negative segment and the HER2-positive segment. HER2-negative breast cancer is the most common type and is usually diagnosed in older patients.